Skip to main content
. 2015 May 11;125(6):2510–2522. doi: 10.1172/JCI80025

Figure 2. ApoB kinetics in lipoprotein fractions after treatment with anacetrapib.

Figure 2

VLDL-, IDL-, and LDL ApoB kinetic parameters for subjects in panel A (n = 29) and panel B (n = 10) at the end of each treatment period. The geometric mean is shown as a bar with unadjusted raw P values generated using a linear mixed-effects model containing fixed effects for panel and treatment-within-panel and random effects for subject-within-panel, unless indicated by an asterisk, in which case median values are indicated by a bar, and P values obtained by a Wilcoxon signed-rank test are shown. ANA, anacetrapib; PBO, placebo.